ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.213,91
-0,08%
S&P 500
5.641,98
0,19%
US Dollar vs BRL
5,4135
-0,64%
Bitcoin
63.655,00
-1,84%
Brent Oil
83,07
-1,51%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Tango Therapeutics Inc (TNGX)

  7. Tango Therapeutics Inc (TNGX) Notícias

TNGX

Tango Therapeutics (TNGX)

Tango Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNGX
DataHoraFonteTítuloCódigoCompanhia
04/01/202404:47PR Newswire (US)Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyNASDAQ:TNGXTango Therapeutics Inc
03/01/202409:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
13/11/202309:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
08/11/202309:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNGXTango Therapeutics Inc
08/11/202309:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNGXTango Therapeutics Inc
08/11/202309:00GlobeNewswire Inc.Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
07/11/202309:00GlobeNewswire Inc.Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:TNGXTango Therapeutics Inc
02/11/202317:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
18/10/202318:23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:TNGXTango Therapeutics Inc
18/09/202308:00GlobeNewswire Inc.Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:TNGXTango Therapeutics Inc
12/09/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TNGXTango Therapeutics Inc
06/09/202308:00GlobeNewswire Inc.Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersNASDAQ:TNGXTango Therapeutics Inc
05/09/202308:00GlobeNewswire Inc.Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TNGXTango Therapeutics Inc
01/09/202308:34Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TNGXTango Therapeutics Inc
31/08/202317:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNGXTango Therapeutics Inc
29/08/202318:08GlobeNewswire Inc.Tango Therapeutics Announces Updates to Its Board of DirectorsNASDAQ:TNGXTango Therapeutics Inc
28/08/202308:00GlobeNewswire Inc.Medicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerNASDAQ:TNGXTango Therapeutics Inc
24/08/202317:10Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:TNGXTango Therapeutics Inc
21/08/202317:16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TNGXTango Therapeutics Inc
10/08/202308:00GlobeNewswire Inc.Tango Therapeutics Announces $80 million Private Placement FinancingNASDAQ:TNGXTango Therapeutics Inc
07/08/202308:00GlobeNewswire Inc.Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
24/07/202308:00GlobeNewswire Inc.Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant CancersNASDAQ:TNGXTango Therapeutics Inc
01/06/202308:00GlobeNewswire Inc.Tango Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:TNGXTango Therapeutics Inc
09/05/202308:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TNGXTango Therapeutics Inc
09/05/202308:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TNGXTango Therapeutics Inc
09/05/202308:00GlobeNewswire Inc.Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:TNGXTango Therapeutics Inc
24/04/202317:48Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:TNGXTango Therapeutics Inc
24/04/202317:41Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TNGXTango Therapeutics Inc
24/04/202317:32Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TNGXTango Therapeutics Inc
18/04/202317:30GlobeNewswire Inc.Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingNASDAQ:TNGXTango Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TNGX

Seu Histórico Recente

LSE
RC2
Reconstruction Capital Ii
LSE
SKG
Smurfit Kappa
NASDAQ
CENT
Central Garden and Pet
NASDAQ
SATC
USOTC
ALIZF
Allianz Ag Muenchen Namen (PK)
NYSE
USPH
US Physical Therapy
NASDAQ
ONXX
LSE
GSD
Goldshield
NASDAQ
RNST
Renasant
LSE
0ODE
Fiducial Real Estate
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados